179 related articles for article (PubMed ID: 38016911)
21. Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape.
Xie X; Lee J; Iwase T; Kai M; Ueno NT
Expert Opin Ther Targets; 2022 May; 26(5):405-425. PubMed ID: 35574694
[TBL] [Abstract][Full Text] [Related]
22. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
Front Oncol; 2022; 12():919072. PubMed ID: 35795050
[TBL] [Abstract][Full Text] [Related]
23. Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer.
Zheng Y; Li S; Tang H; Meng X; Zheng Q
Front Immunol; 2023; 14():1153990. PubMed ID: 37426654
[TBL] [Abstract][Full Text] [Related]
24. Clinical trials of immunotherapy in triple-negative breast cancer.
Howard FM; Pearson AT; Nanda R
Breast Cancer Res Treat; 2022 Aug; 195(1):1-15. PubMed ID: 35834065
[TBL] [Abstract][Full Text] [Related]
25. Progress and challenges of immunotherapy in triple-negative breast cancer.
Zhu Y; Zhu X; Tang C; Guan X; Zhang W
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188593. PubMed ID: 34280474
[TBL] [Abstract][Full Text] [Related]
26. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
[TBL] [Abstract][Full Text] [Related]
27. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer.
Chen X; Feng L; Huang Y; Wu Y; Xie N
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612100
[TBL] [Abstract][Full Text] [Related]
29. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Steiner M; Tan AR
Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
[TBL] [Abstract][Full Text] [Related]
30. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
32. Immune-related biomarkers in triple-negative breast cancer.
Zhang J; Tian Q; Zhang M; Wang H; Wu L; Yang J
Breast Cancer; 2021 Jul; 28(4):792-805. PubMed ID: 33837508
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in targeted strategies for triple-negative breast cancer.
Zhu S; Wu Y; Song B; Yi M; Yan Y; Mei Q; Wu K
J Hematol Oncol; 2023 Aug; 16(1):100. PubMed ID: 37641116
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer.
Munkácsy G; Santarpia L; Győrffy B
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108109
[TBL] [Abstract][Full Text] [Related]
35. Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.
Qattan A
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255471
[TBL] [Abstract][Full Text] [Related]
36. Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.
Tan Q; Yin S; Zhou D; Chi Y; Man X; Li H
Front Oncol; 2022; 12():779786. PubMed ID: 35646659
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
Liang X; Chen X; Li H; Li Y
Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
[TBL] [Abstract][Full Text] [Related]
38. Role of Immunotherapy in Breast Cancer.
Jacob SL; Huppert LA; Rugo HS
JCO Oncol Pract; 2023 Apr; 19(4):167-179. PubMed ID: 36608303
[TBL] [Abstract][Full Text] [Related]
39. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
Yang Z; Sun JK; Lee MM; Chan MK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
[TBL] [Abstract][Full Text] [Related]
40. Novel immunotherapies for breast cancer: Focus on 2023 findings.
Lan HR; Chen M; Yao SY; Chen JX; Jin KT
Int Immunopharmacol; 2024 Feb; 128():111549. PubMed ID: 38266449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]